Inhibition of PCSK9 in familial hypercholesterolaemia

被引：5
|
作者：
Sijbrands, Eric J. G. [1 ,2 ]
机构：
[1] Erasmus MC, Pharmacol Vasc & Metab Dis sect, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
[2] Erasmus MC, Dept Cardiol & Internal Med, Cardiovasc Genet Sect, NL-3000 CA Rotterdam, Netherlands
来源：
LANCET | 2012年 / 380卷 / 9836期
关键词：
APOLIPOPROTEIN-B; CONTROLLED-TRIAL; LDL CHOLESTEROL; DOUBLE-BLIND; STATIN; ATHEROSCLEROSIS; MIPOMERSEN; EZETIMIBE; EFFICACY; THERAPY;
D O I：
10.1016/S0140-6736(12)60814-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [31] Latest clinical evidence about the effect of PCSK9 monoclonal antibodies in patients with familial hypercholesterolaemia: an updated meta-analysis
    Zhang, Qiongfang
    Deng, Lianxiang
    Chen, Cong
    Pan, Xu
    Jiang, Shan
    ENDOKRYNOLOGIA POLSKA, 2022, 73 (01) : 110 - 120
  • [32] Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
    Reyes-Soffer, Gissette
    Pavlyha, Marianna
    Ngai, Colleen
    Thomas, Tiffany
    Holleran, Stephen
    Ramakrishnan, Rajasekhar
    Karmally, Wahida
    Nandakumar, Renu
    Fontanez, Nelson
    Obunike, Joseph
    Marcovina, Santica M.
    Lichtenstein, Alice H.
    Matthan, Nirupa R.
    Matta, James
    Maroccia, Magali
    Becue, Frederic
    Poitiers, Franck
    Swanson, Brian
    Cowan, Lisa
    Sasiela, William J.
    Surks, Howard K.
    Ginsberg, Henry N.
    CIRCULATION, 2017, 135 (04) : 352 - +
  • [33] PCSK9 inhibition: the way forward in the treatment of dyslipidemia
    Stoekenbroek, Robert M.
    Kastelein, John J. P.
    Huijgen, Roeland
    BMC MEDICINE, 2015, 13
  • [34] Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
    Raal, Frederick J.
    Honarpour, Narimon
    Blom, Dirk J.
    Hovingh, G. Kees
    Xu, Feng
    Scott, Rob
    Wasserman, Scott M.
    Stein, Evan A.
    Investigators, T. E. S. L. A.
    LANCET, 2015, 385 (9965) : 341 - 350
  • [35] PCSK9 inhibitors
    Gencer, Baris
    Lambert, Gilles
    Mach, Francois
    SWISS MEDICAL WEEKLY, 2015, 145
  • [36] PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials
    Benhuri, Benjamin
    Ueyama, Hiroki
    Takagi, Hisato
    Briasoulis, Alexandros
    Kuno, Toshiki
    CURRENT VASCULAR PHARMACOLOGY, 2021, 19 (04) : 390 - 397
  • [37] Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
    O'Donoghue, Michelle L.
    Fazio, Sergio
    Giugliano, Robert P.
    Stroes, Erik S. G.
    Kanevsky, Estella
    Gouni-Berthold, Ioanna
    Im, KyungAh
    Pineda, Armando Lira
    Wasserman, Scott M.
    Ceska, Richard
    Ezhov, Marat V.
    Jukema, J. Wouter
    Jensen, Henrik K.
    Tokgozoglu, S. Lale
    Mach, Francois
    Huber, Kurt
    Sever, Peter S.
    Keech, Anthony C.
    Pedersen, Terje R.
    Sabatine, Marc S.
    CIRCULATION, 2019, 139 (12) : 1483 - 1492
  • [38] A Comprehensive Review of PCSK9 Inhibitors
    Coppinger, Caroline
    Movahed, Mohammad Reza
    Azemawah, Veronica
    Peyton, Lee
    Gregory, James
    Hashemzadeh, Mehrnoosh
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022, 27
  • [39] Getting Real With PCSK9 Inhibitors in Familial Hypercholesterolemia
    Baass, Alexis
    Hegele, Robert A.
    CANADIAN JOURNAL OF CARDIOLOGY, 2018, 34 (08) : 959 - 961
  • [40] The evolving landscape of PCSK9 inhibition in cancer
    Oza, Palak P.
    Kashfi, Khosrow
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 949
12345